About Histogenics
Histogenics is a company based in Waltham (United States) founded in 2000.. Histogenics has raised $115.72 million across 6 funding rounds from investors including Stryker, Gimv and Sofinnova. The company has 69 employees as of December 31, 2024. Histogenics has completed 1 acquisition, including ProChon Biotech. Histogenics operates in a competitive market with competitors including Horizon Therapeutics, Tenaya Therapeutics, Athira Pharma, Ensoma and Orca Bio, among others.
- Headquarter Waltham, United States
- Employees 69 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ocugen, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$115.72 M (USD)
in 6 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Sep 16, 2016
-
Investors
Stryker
& 7 more
-
Employee Count
69
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Finance and Accounting
1 people
Leadership Team
1 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Histogenics
Histogenics has successfully raised a total of $115.72M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(22 Aug 2006)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2016 | Amount | Post-IPO - Histogenics | Valuation |
investors |
|
| Jan, 2014 | Amount | Series C - Histogenics | Valuation |
investors |
|
| Jul, 2012 | Amount | Series C - Histogenics | Valuation | Sofinnova Investments |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Histogenics
Histogenics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Stryker, Gimv and Sofinnova. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
US venture capital investments are made across all stages.
|
Founded Year | Domain | Location | |
|
US-focused private equity and venture capital investments are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Histogenics
Histogenics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ProChon Biotech. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Regenerative biology products for cartilage lesions are developed and commercialized.
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Histogenics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Histogenics Comparisons
Competitors of Histogenics
Histogenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Tenaya Therapeutics, Athira Pharma, Ensoma and Orca Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
|
|
| domain | founded_year | HQ Location |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Products for regenerative and respiratory medicine are developed and distributed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Histogenics
Frequently Asked Questions about Histogenics
When was Histogenics founded?
Histogenics was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Where is Histogenics located?
Histogenics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Histogenics a funded company?
Histogenics is a funded company, having raised a total of $115.72M across 6 funding rounds to date. The company's 1st funding round was a Series C of $49M, raised on Aug 22, 2006.
How many employees does Histogenics have?
As of Dec 31, 2024, the latest employee count at Histogenics is 69.
What does Histogenics do?
Histogenics was founded in 2000 and is headquartered in Waltham, United States. Focus is placed on the development of restorative cell therapies within the biotechnology sector, targeting orthopedic conditions. Operations center on proprietary regenerative technologies, including the flagship product NeoCart, by which patients knee cartilage is rebuilt using their own cells. Pain associated with cartilage damage is addressed directly, with potential to halt osteoarthritis advancement.
Who are the top competitors of Histogenics?
Histogenics's top competitors include Horizon Therapeutics, Tenaya Therapeutics and Athira Pharma.
How many acquisitions has Histogenics made?
Histogenics has made 1 acquisition, including ProChon Biotech.
Who are Histogenics's investors?
Histogenics has 8 investors. Key investors include Stryker, Gimv, Sofinnova, Split Rock Partners, and Altima Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.